Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 14.91M | 14.29M | 12.73M | 13.27M | 12.63M | 18.63M |
Gross Profit | 5.62M | 5.46M | 4.75M | 4.48M | 3.99M | 6.56M |
EBITDA | -3.53M | -3.57M | -4.53M | -4.45M | -5.70M | -3.22M |
Net Income | -3.56M | -3.46M | -4.83M | -5.15M | -5.09M | -3.95M |
Balance Sheet | ||||||
Total Assets | 14.59M | 13.69M | 14.74M | 16.23M | 18.84M | 14.99M |
Cash, Cash Equivalents and Short-Term Investments | 3.60M | 5.37M | 3.13M | 3.82M | 7.40M | 4.22M |
Total Debt | 675.00K | 305.00K | 608.00K | 849.00K | 1.37M | 2.67M |
Total Liabilities | 10.54M | 9.28M | 8.60M | 8.25M | 10.15M | 9.62M |
Stockholders Equity | 4.06M | 4.41M | 6.14M | 7.98M | 8.70M | 5.36M |
Cash Flow | ||||||
Free Cash Flow | -1.37M | -168.00K | -2.42M | -6.42M | -4.38M | -3.56M |
Operating Cash Flow | -1.19M | -88.00K | -2.40M | -6.15M | -4.25M | -3.38M |
Investing Cash Flow | -181.00K | -80.00K | -2.00K | -258.00K | -99.00K | 388.00K |
Financing Cash Flow | 2.34M | 3.03M | 1.68M | 2.49M | 7.40M | 3.31M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
46 Neutral | 6.11M | -1.24 | -61.13% | ― | -29.64% | 73.63% | |
46 Neutral | 7.64M | -1.71 | ― | ― | 70.02% | 82.33% | |
46 Neutral | 6.65M | -0.56 | -24.55% | ― | 19.22% | 98.73% | |
45 Neutral | $6.64M | ― | -78.73% | ― | 17.43% | 75.52% | |
41 Neutral | 6.13M | ― | ― | ― | ― | ― | |
32 Underperform | 4.29M | -0.07 | ― | ― | ― | 31.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On August 27, 2025, Sonoma Pharmaceuticals held its annual stockholders meeting where several key proposals were voted on. Dr. Jay Birnbaum was elected as a Class II director, executive compensation for the year ended March 31, 2025, was approved, Frazier & Deeter, LLC was ratified as the independent registered public accounting firm for the fiscal year ending March 31, 2026, and a proposal to adjourn the meeting for further proxy solicitation was also approved.